Bloomberg News

Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study

April 19, 2012

Bristol-Myers Squibb Co. (BMY:US) said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.

Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.

In a separate mid-stage study, Bristol-Myers’ experimental peginterferon lambda drug had a cure rate similar to peginterferon alfa with fewer side effects, the company said.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Steve Ballmer, Power Forward
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • BMY
    (Bristol-Myers Squibb Co)
    • $51.49 USD
    • 0.93
    • 1.81%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus